AbbVie’s Allergen Aesthetics received European Commission approval for Boey to treat moderate-to-severe glabellar lines between the eyebrows in adults. The regulatory green light expands the product’s commercial opportunity in Europe, a modest positive catalyst for the company.
AbbVie’s Allergen Aesthetics received European Commission approval for Boey to treat moderate-to-severe glabellar lines between the eyebrows in adults. The regulatory green light expands the product’s commercial opportunity in Europe, a modest positive catalyst for the company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
